External broker reports(aggregated public sources), Daishin Securities

Daishin Securities

External broker reports(aggregated public sources)

Founded in 1962, Daishin Securities is a leading financial services provider in Korea. Daishin securities does its best to provide high quality financial service and to satisfy the various needs of investors. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>The FDA approved the lazertinib+amivantamab therapy on Aug 20 </li><li>A monumental case for a local anti-cancer drug to get FDA approval for commercial use in the US</li><li>Commercialization also likely in other countries, with milestone payments anticipated</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

The FDA approved the lazertinib+amivantamab therapy on Aug 20 A monumental case for a local anti-cancer drug to get FDA approval for commercial use in the USCommercialization also likely in other countries, with milestone payments anticipatedContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Oscotec (039200 KQ) - Birth of a Proud K-Blockbuster

Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Korea/Asia, Events, IPOs

Douglas Research Advisory

Event-Driven

<ul>
<li>On 16 August, Peptron (087010 KS) announced that it decided to increase capital through a rights offering worth about 120 billion won, involving 2.64 million shares (12.8% of outstanding shares). </li>
<li>The expected rights offering price is 45,450 won, which is 22% lower than current price.</li>
<li>We are negative on Peptron's rights offering mainly due to much lower expected rights offering price, concerns about additional rights offering next 2-3 years, and continued lack of profitability.</li>
</ul>


On 16 August, Peptron (087010 KS) announced that it decided to increase capital through a rights offering worth about 120 billion won, involving 2.64 million shares (12.8% of outstanding shares). 
The expected rights offering price is 45,450 won, which is 22% lower than current price.
We are negative on Peptron's rights offering mainly due to much lower expected rights offering price, concerns about additional rights offering next 2-3 years, and continued lack of profitability.


Peptron: Rights Offering of 120 Billion Won

South Korea

Oscotec Inc. manufactures bone and dental related medical equipment. The Company also produces a wide range of bone related medicine such as medicine to cure osteoporosis, arthritis, periodontal, and also provides R & D service.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Oscotec Inc (039200 KS)

Oscotec (039200 KQ) - Birth of a Proud K-Blockbuster

The FDA approved the lazertinib+amivantamab therapy on Aug 20. A monumental case for a local anti-cancer drug to get FDA approval for commercial...

Daishin Securities

Peptron: Rights Offering of 120 Billion Won

On 16 August, Peptron (087010 KS) announced that it decided to increase capital through a rights offering worth about 120 billion won, involving...

Douglas Kim

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)